Edward Tenthoff
Stock Analyst at Piper Sandler
(2.26)
# 2,740
Out of 4,980 analysts
177
Total ratings
41.18%
Success rate
-2.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $304 → $449 | $482.13 | -6.87% | 14 | Aug 1, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $5.13 | +192.40% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $2.75 | +81.82% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $53.69 | +95.57% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.97 | +106.04% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.86 | +276.34% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $7.24 | +24.31% | 4 | May 29, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $8.00 | +75.00% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.50 | +297.69% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $13.26 | +262.13% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.00 | +60.00% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $34.25 | +127.74% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $8.31 | +261.01% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $27.73 | +62.28% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $24.47 | +181.98% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $11.00 | +490.91% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.99 | +804.52% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.48 | +440.12% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.12 | +385.44% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.41 | +112.77% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.77 | +289.16% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.83 | +231.26% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $0.98 | +512.31% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.72 | +190.70% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $43.48 | +28.79% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $13.60 | +1,723.53% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.28 | +2,643.90% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $18.65 | +865.41% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.75 | +162.69% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.12 | +419.66% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.53 | +42,561,991.50% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $767.00 | -53.85% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.46 | +9,146.58% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $396.48 | -18.53% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $38.28 | -5.96% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $0.85 | +2,837.72% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.64 | +9,046.34% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.45 | +308,279.89% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $556.53 | - | 11 | Feb 13, 2017 |
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $304 → $449
Current: $482.13
Upside: -6.87%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $5.13
Upside: +192.40%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $2.75
Upside: +81.82%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $53.69
Upside: +95.57%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.97
Upside: +106.04%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.86
Upside: +276.34%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $7.24
Upside: +24.31%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $8.00
Upside: +75.00%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.50
Upside: +297.69%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $13.26
Upside: +262.13%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.00
Upside: +60.00%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $34.25
Upside: +127.74%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $8.31
Upside: +261.01%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $27.73
Upside: +62.28%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $24.47
Upside: +181.98%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $11.00
Upside: +490.91%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.99
Upside: +804.52%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $6.48
Upside: +440.12%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.12
Upside: +385.44%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.41
Upside: +112.77%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.77
Upside: +289.16%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.83
Upside: +231.26%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $0.98
Upside: +512.31%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.72
Upside: +190.70%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $43.48
Upside: +28.79%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $13.60
Upside: +1,723.53%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.28
Upside: +2,643.90%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $18.65
Upside: +865.41%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.75
Upside: +162.69%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.12
Upside: +419.66%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.53
Upside: +42,561,991.50%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $767.00
Upside: -53.85%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.46
Upside: +9,146.58%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $396.48
Upside: -18.53%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $38.28
Upside: -5.96%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $0.85
Upside: +2,837.72%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.64
Upside: +9,046.34%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.45
Upside: +308,279.89%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $556.53
Upside: -